Last reviewed · How we verify
latanoprost 0.005% ophthalmic solution
At a glance
| Generic name | latanoprost 0.005% ophthalmic solution |
|---|---|
| Also known as | xalatan, Latanoprost, Xalatan®, Xalatan, Microneedling using Dr Pen Derma Pen Ultima A6® |
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients (PHASE4)
- Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension (PHASE2, PHASE3)
- Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment
- Rocklatan vs Latanoprost Post-DSLT (PHASE4)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Optic Nerve Head Strain in Non-glaucoma Subjects (EARLY_PHASE1)
- Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (PHASE3)
- Next Generation Rocklatan (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |